6-Mercaptopurine-induced alterations in mineral metabolism and teratogenesis in the rat.
The relationship between 6-mercaptopurine-induced alterations in mineral metabolism and the teratogenic effects of the drug were investigated. Pregnant Sprague-Dawley rats were fed diets containing 4.5, 100, or 1,000 micrograms Zn per 1 g diet. On day 11 of gestation, dams were given intraperitoneal injections of 6-mercaptopurine (27.5 mg/kg). At term, dams fed the 1,000-micrograms Zn per 1 g diet showed fewer drug-induced deleterious effects on reproduction and embryogenesis than did those fed lower levels of zinc. Mineral analysis of maternal and fetal tissues revealed pronounced effects of 6-mercaptopurine on metabolism of zinc, copper, iron, calcium, and magnesium. The results of this study indicate that 6-mercaptopurine teratogenesis may be due in part to drug-induced changes in mineral metabolism.
D000014:Abnormalities, Drug-Induced; D000818:Animals; D002118:Calcium / Q000378:metabolism; D003300:Copper / Q000378:metabolism; D005260:Female; D005333:Fetus / Q000187:drug effects / Q000378:metabolism; D007501:Iron / Q000378:metabolism; D008274:Magnesium / Q000378:metabolism; D008431:Maternal-Fetal Exchange; D015122:Mercaptopurine / Q000494:pharmacology / Q000633:toxicity*; D008903:Minerals / Q000378:metabolism*; D009929:Organ Size / Q000187:drug effects; D010920:Placenta / Q000033:anatomy & histology; D011247:Pregnancy; D051381:Rats; D014018:Tissue Distribution; D015032:Zinc / Q000008:administration & dosage / Q000378:metabolism
D008903:Minerals; D003300:Copper; D007501:Iron; D015122:Mercaptopurine; D008274:Magnesium; D015032:Zinc; D002118:Calcium